Logo for Halozyme Therapeutics Inc

Halozyme Therapeutics Investor Relations Material

Latest events

Logo for Halozyme Therapeutics Inc

Q4 2023

Halozyme Therapeutics
Logo for Halozyme Therapeutics

Q4 2023

20 Feb, 2024
Logo for Halozyme Therapeutics

Investor Update

17 Jan, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Segment Data
Access more data
Revenue by
Geography
Royalties
Product sales
Revenues under collaborative agreements
Expenses by
Financials
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes novel oncology therapies in the United States and internationally. Its human enzymes are based on intellectual property covering the family of human enzymes known as hyaluronidases. The company operates in two segments, Enhanze Technology, and Clinical Development Pipeline Products. The Enhanze Technology segment engages in the research and development of product candidates that use its proprietary technology platform to develop subcutaneous formulations of injectable biologics.